The potential for liquid biopsies in the precision medical treatment of breast cancer

在线阅读 下载PDF 导出详情
摘要 Currentlytheclinicalmanagementofbreastcancerreliesonrelativelyfewprognostic/predictiveclinicalmarkers(estrogenreceptor,progesteronereceptor,HER2),basedonprimarytumorbiology.Circulatingbiomarkers,suchascirculatingtumorDNA(ctDNA)orcirculatingtumorcells(CTCs)mayenhanceourtreatmentoptionsbyfocusingontheverycellsthatarethedirectprecursorsofdistantmetastaticdisease,andprobablyinherentlydifferentthantheprimarytumor'sbiology.Toshiftthecurrentclinicalparadigm,assessingtumorbiologyinrealtimebymolecularlyprofilingCTCsorctDNAmayservetodiscovertherapeutictargets,detectminimalresidualdiseaseandpredictresponsetotreatment.Thisreviewservestoelucidatethedetection,characterization,andclinicalapplicationofCTCsandctDNAwiththegoalofprecisiontreatmentofbreastcancer.
机构地区 不详
出版日期 2016年01月11日(中国期刊网平台首次上网日期,不代表论文的发表时间)
  • 相关文献